Connecting patients to better treatment & improved health: the journey of AICure

Hewlett Packard Enterprise installs new signage on the exterior of its Palo Alto, CA headquarters. CREDIT: Hewlett Packard Enterprise
Exclusive Interview with Hewlett Packard Enterprise – The Augmented Intelligence Opportunity
January 28, 2016
sunny_go_board_by_kageneko3-d5bnd4w
Google DeepMind Victorious In Beating Grandmaster In The Game Of Go
February 1, 2016

Connecting patients to better treatment & improved health: the journey of AICure

AiCure_artificial_intelligence_confirms_medication_ingestion

AICure recently grabbed the headlines in the AI start-up universe with a highly successful financing round. AIBusiness.org met with Adam Hanina, CEO of AICure for an exclusive interview in New York City. Adam shared his vision of AI helping patients achieve improved health as well as a sense that someone is always looking after them, even outside of clinic visits. 

Tell us about your journey so far with AICure – what was the inspiration for the business, and what are you aiming to achieve?

We’re solving a really big problem. Hundreds of billions of dollars are lost in failed trials and expensive hospitalization because patient behavior is not well understood. At AiCure, we use artificial intelligence to visually confirm medication ingestion. By measuring behavior that impacts the outcomes of clinical trials and patient health, we can have a direct impact on these areas. Our aim as an organization is to connect patients to better treatment and improved health, on a global scale.

The journey has been fantastic. I’ve been working at the intersection of technology and healthcare for over fifteen years. In the late 1990s, concepts like buying medication online or communicating through text messages seemed strange. Now, those are commonplace. Technology has evolved so quickly that smartphones now have sufficient processing power to handle artificial intelligence applications that utilize complex computer vision and machine learning algorithms. So timing has certainly been an important factor in our development. The second thing that was critical for our evolution was funding from the National Institutes of Health. Although the funding was extremely competitive, it really validated our approach. Our recent venture financing was another inflection point that has allowed us to scale the organization in many ways that will extend our reach further.

Can you give a brief overview of your proposition, as the first power-efficient health monitoring proposition?

At AiCure, our intelligent platform has been designed to positively impact patient behavior and medication adherence – this translates across all therapeutic areas. Improved adherence leads to increased statistical power in clinical research and improved health outcomes in population health. These vertical markets are significant.

Would you like to share a couple of your case-studies/success stories?

While I was attending a large conference in San Francisco the other day, one of our clients approached me to thank me for saving his drug trial. He told me that he would not have been able to complete his clinical trial had it not been for our technology. We were able to give him unique real-time insights into patient behavior that his team were able to incorporate into their analysis. Similarly, in one of the trials we are running in an elderly population, patients wanted to keep on using our technology after the end of the trial. They felt that the platform gave them greater continuity of care and the sense that somebody was looking after them outside of clinic visits.

AiCure_Adam_Hanina

AICure CEO Adam Hanina

 

What’s next for AICure?

Our artificial intelligence platform keeps getting smarter and uniquely adapting to different patient populations. We’re focusing on data validation and scaling up. Since the app works on many different devices, even $8 smartphones that are available all over the world, AiCure is in a unique position to have global impact in clinical trials and population health. We’re busy getting ready for that expansion.

Which Industries do you believe will be the pioneers in broadly adopting AI technologies? Is Pharma one of them?

In the pharmaceutical industry, AI is becoming critical to the way data are collected, measured and even improved. In some cases AI is invisible to the end user, while in other cases the technology is more obvious. The knowledge and data obtained through AI, whether it be clinical research or population health, is going to open up new possibilities for personalized medicine and provide insights that we have never seen before.

How do you see the Enterprise AI market evolving over the next 5 years?

Incorporating AI into everyday life is already happening. Whether it’s advances in ‘deep learning’ neural networks, AI diagnoses, or using facial recognition to understand our emotions, the AI market is evolving at a dizzying speed not just in medicine but across all areas of life. The most exciting part, I believe, will be our ability to quantify the positive impact that AI has on our society and extend these benefits to everyone.

Leave a Reply

Translate »

We use cookies. By browsing our site you agree to our use of cookies.Accept